Increased Salt Sensitivity of Ambulatory Blood Pressure in Women With a History of Severe Preeclampsia

Sponsor
University Hospital, Geneva (Other)
Overall Status
Completed
CT.gov ID
NCT01874990
Collaborator
(none)
40
1
2
36
1.1

Study Details

Study Description

Brief Summary

Cardiovascular diseases are the principal cause of death in women in developed and developing countries and are importantly promoted by hypertension. Salt sensitivity of the blood pressure is considered as an important cardiovascular risk factor at any blood pressure level. Severe preeclampsia is a hypertensive disorder of the pregnancy that also arises as a risk factor for cardiovascular and renal diseases.

The major aim of this study is to examine the salt sensitivity of the ambulatory blood pressure in women with a history of severe preeclampsia (< 34 weeks gestation) compared with women with no history of pregnancy-related hypertensive complications. We plan to recruit 20 non-menopausal women with a history of severe preeclampsia, and 20 age, parity, race- matched premenopausal women as controls. The study has a case control randomized design. The salt sensitivity of the ambulatory blood pressure is defined as an increase of ≥4 mmHg in 24h ambulatory blood pressure on a high sodium diet. The high sodium diet is obtained by adding capsules of 6gr of NaCl/ day in the usual diet.

The participants are identified as women discharged from the Maternity of University Hospital of Geneva between 1999 and 2001 with a preeclampsia coding. Fetal and maternal data will be carefully recovered from hospital records to identify severe preeclampsia (PE), based on International Society for the Study of Hypertension in Pregnancy criteria. These criteria are systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥110 mmHg with severe proteinuria (≥ 5g /24h or 3+ dipstick) and one or more signs of multisystem disease developing after 20 weeks of gestation in previously normotensive women. Severe preeclampsia was also defined as occurring before 34wk of gestation. Women with a history of hypertension, diabetes mellitus, renal or cardiac impairment, polycystic ovary syndrome will be excluded. Other exclusion criteria are anti-inflammatory drugs, diuretics, aspirin, oral contraceptives and hormonal replacement therapy. The protocol is approved by the University Hospital Ethical Committee and written informed consent will be obtained from each individual in accordance with the declaration of Helsinki. The study is conducted between 2009 and 2012 at the University Hospitals of Geneva, Switzerland.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: high sodium diet
  • Dietary Supplement: low-salt diet
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Study Start Date :
Dec 1, 2009
Actual Primary Completion Date :
Nov 1, 2011
Actual Study Completion Date :
Dec 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: women with a history of severe preeclampsia

women with a history of severe preeclampsia(< 34 weeks gestation) between 5 and 10 years ago

Dietary Supplement: high sodium diet
The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet

Dietary Supplement: low-salt diet

Experimental: control

women with no history of pregnancy-related hypertensive complications

Dietary Supplement: high sodium diet
The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet

Dietary Supplement: low-salt diet

Outcome Measures

Primary Outcome Measures

  1. salt sensitivity of the ambulatory blood pressure in women with a history of severe preeclampsia (< 34 weeks gestation) compared with women with no history of pregnancy-related hypertensive complications [evaluation at 5wk]

    The women receive a low-sodium (LS) and a high-sodium (HS) diet for 1 week. The sequence of the diets is randomized in order to prevent a sequence effect. Between the two periods, they retain their usual diet for 3 weeks. The high-sodium diet is obtained by adding 6g of sodium chloride to the individual's regular diet. On day 7 of each dietary period, 24h ambulatory BP is recorded. Automated measurements are performed every 30 min intervals from 08:00 to 22:00 hours and at 60 min from 22:00 to 08:00 hours. The primary measure outcome is the response of the mean, or systolic, or diastolic ambulatory blood pressure to a high salt diet compared with low salt diet in PEC women and in controls. Salt-sensitivity is defined by an increase of at least 4 mmHg on a high salt diet.

Secondary Outcome Measures

  1. Variability of the ambulatory blood pressure on a high salt diet [evaluation at 5wk]

    A secondary outcome measure will be to assess the variability of the ambulatory blood pressure on differents salt diets, assessed by the standard deviation of the BP

Other Outcome Measures

  1. occurence of a cardiovascular event in women having suffered from a preeclampsia [5 years]

    we will assess at 5 years, the time between the delivery and the occurence of a cardiovascular event in post-preeclamptic women depending of their salt-sensitivity.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • women with history of severe preeclampsia (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥110 mmHg with severe proteinuria (≥ 5g /24h or 3+ dipstick) and one or more signs of multisystem disease developing after 20 weeks of gestation in previously normotensive women.

or

  • women who had a premature delivery (<34 weeks) in the context of preeclampsia (systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90 mmHg with severe proteinuria (≥ 300 mg /24h or 1+ dipstick)

  • age ≤ 50 years

  • controls : women and who delivered at term (> 37 weeks) without pre-eclampsia

Exclusion Criteria:
History of :
  • hypertension

  • diabetes mellitus

  • renal or cardiac impairment

  • polycystic ovary syndrome

  • recent or actual use of anti-inflammatory drugs, diuretics, aspirin, oral contraceptives and hormonal replacement therapy

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospitals Geneva 14 Switzerland 1211

Sponsors and Collaborators

  • University Hospital, Geneva

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Antoinette Pechere-Bertschi, MD, Principal Investigator, University Hospital, Geneva
ClinicalTrials.gov Identifier:
NCT01874990
Other Study ID Numbers:
  • Preeclampsia &salt sensitivity
First Posted:
Jun 11, 2013
Last Update Posted:
Jun 11, 2013
Last Verified:
Apr 1, 2013
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 11, 2013